These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23208343)

  • 1. A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement.
    Hossain NM; Jain N; Steinmetz JL; McConville JF; Anastasi J; Odenike O
    Chest; 2012 Dec; 142(6):1680-1683. PubMed ID: 23208343
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.
    Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
    Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.
    Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A
    Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.
    Srinivas U; Barwad A; Pubbaraju SV
    Br J Haematol; 2014 Jun; 165(5):583. PubMed ID: 24456122
    [No Abstract]   [Full Text] [Related]  

  • 5. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib-responsive hypereosinophilic syndrome.
    Robyn J
    Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
    Kobayashi M; Kubota T; Uemura Y; Taguchi H
    Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of FIP1L1-PDGFRA fusion by FISH.
    Ma ES; Wong KF; Wong CL; Siu LL
    Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
    [No Abstract]   [Full Text] [Related]  

  • 9. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
    Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
    Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
    Srinivasan A; Scordino T; Baker A
    J Pediatr Hematol Oncol; 2019 May; 41(4):334-335. PubMed ID: 30807397
    [No Abstract]   [Full Text] [Related]  

  • 11. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
    Helbig G; Kyrcz-Krzemień S
    Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
    [No Abstract]   [Full Text] [Related]  

  • 13. Eosinophilia: secondary, clonal and idiopathic.
    Tefferi A; Patnaik MM; Pardanani A
    Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
    Jain N; Khoury JD; Pemmaraju N; Kollipara P; Kantarjian H; Verstovsek S
    Blood; 2013 Nov; 122(19):3387-8. PubMed ID: 24203930
    [No Abstract]   [Full Text] [Related]  

  • 15. FIP1L1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
    Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
    Winter L; Zellweger MJ; Bremerich J
    Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
    [No Abstract]   [Full Text] [Related]  

  • 19. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report.
    Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C
    Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.